Diagnosis and treatment of melanoma brain metastasis: A literature review

Cancer Control

Volumn 16, Issue 3, 2009, Pages 248-255

  Sloan, Andrew E ^a   Nock, Charles J ^a   Einstein, Douglas B ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; LOMUSTINE; TEMOZOLOMIDE; THALIDOMIDE;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG FATALITY; DRUG MEGADOSE; HUMAN; LUNG EMBOLISM; MELANOMA; MENINGEAL METASTASIS; METASTASIS; MICROSURGERY; RADIOSURGERY; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 67650529123     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600307     Document Type: Review

References (68)

1. Wen PY, Black PM, Loeffler JS. Treatment of metastatic brain cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14): 2865-2872. (Pubitemid 41079905)
3. Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer. 1978;14(4):327-330. (Pubitemid 8310441)
4. Bullard DE, Cox EB, Seigler HF. Central nervous system metastases in malignant melanoma. Neurosurgery. 1981;8(1):26-30. (Pubitemid 11146127)
5. Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660-668. (Pubitemid 8405861)
6. Sampson JH, Carter JH Jr, Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88(1):11-20. (Pubitemid 28018958)
7. Choi KN, Withers HR, Rotman M. Metastatic melanoma in brain: rapid treatment or large dose fractions. Cancer. 1985;56(1):10-15. (Pubitemid 15022847)
8. Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61(9):1926-1934. (Pubitemid 18112779)
9. Salvati M, Cervoni L, Caruso R, et al. Solitary cerebral metastasis from melanoma: value of the 'en block' resection. Clin Neurol Neurosurg. 1996;98(1):12-14.
10. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007;109(3):455-464. (Pubitemid 46190953)
11. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181(3):193-201.
12. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7): 1293-1300. (Pubitemid 41079844)
13. Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol. 1996;12(6):429-435.
14. Stevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol. 1992;23(3):185-191.
15. Kanner A, Barnett GH. Management of brain metastasis in malignant melanoma patients. In: Sawaya R, ed. Treatment of Metastatic Brain Tumors. Oxford, UK: Futura Blackwell; 2004.
16. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4): 745-751. (Pubitemid 27181303)
17. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. (Pubitemid 20067825)
18. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583-590. (Pubitemid 23161878)
19. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470-1476. (Pubitemid 26317868)
20. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485-1489. (Pubitemid 28507400)
21. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29(4):711-717. (Pubitemid 24241310)
22. Muacevic A, Wowra B, Siefert A, et al. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol. 2008;87(3):299-307. Epub 2007 Dec 22.
23. Sause WT, Scott C, Krisch R, et al. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys. 1993;26(4):653-657. (Pubitemid 23220165)
24. Bindal RK, Sawaya R, Leavens ME, et al. Surgical treatment of multiple brain metastases. J Neurosurg. 1993;79(2):210-216. (Pubitemid 23215837)
25. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-1672. (Pubitemid 38670323)
26. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2):427-434. (Pubitemid 29408559)
27. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-2491. (Pubitemid 43854963)
28. Carella RJ, Gelber R, Hendrickson F, et al. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980;45(4):679-683. (Pubitemid 10174607)
29. Morris SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004;91(5):829-833. (Pubitemid 39273770)
30. Buchsbaum JC, Suh JH, Lee SY, et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94(8):2265-2272. (Pubitemid 34411986)
31. Brown PD, Brown CA, Pollock BE, et al. Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery. 2002;51(3): 656-665; discussion 665-667.
32. Selek U, Chang EL, Hassenbusch SJ 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59(4):1097-1106. (Pubitemid 38834303)
33. Mathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007; 54:241-247. (Pubitemid 46339184)
34. DiLuna ML, King JT Jr, Knisely JP, et al. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer. 2007;109(1):135-145. (Pubitemid 46127203)
35. Mori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42(3):581-589. (Pubitemid 28501108)
36. Lavine SD, Petrovich Z, Cohen-Gadol AA, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery. 1999;44(1):59-64; discussion 64-66. (Pubitemid 29016167)
37. Samlowski WE, Watson GA, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109(9):1855-1862. (Pubitemid 46668551)
38. Manon R, O'Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005;23(34):8870-8876. (Pubitemid 46211534)
39. Yamamoto M, Ide M, Nishio S, et al. Gamma Knife radiosurgery for numerous brain metastases: is this a safe treatment? Int J Radiat Oncol Biol Phys. 2002;53(5):1279-1283. (Pubitemid 34787865)
40. Tsao H, Atkins MB, Sober AJ. Management of cutaneous mela - noma. N Engl J Med. 2004;351(10):998-1012.
41. Erratum in: N Engl J Med. 2004;351(23):2461.
42. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66(9):1873-1878. (Pubitemid 20385954)
43. Jacquillat C, Khayat D, Banzet P, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol. 1990;25(4):263-266. (Pubitemid 20014969)
44. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118-1125. (Pubitemid 41095046)
45. Larkin JM, Hughes SA, Beirne DA, et al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer. 2007;96(1):44-48. Epub 2006 Dec 5. (Pubitemid 46094637)
46. Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003;13(1):97-103. (Pubitemid 36269821)
47. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158- 166.
48. Erratum in: J Clin Oncol. 2000;18(11):2351.
49. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21(13): 2551-2557. (Pubitemid 46606337)
50. Richtig E, Soyer HP, Posch M, et al. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol. 2005;23(34):8655-8663. Epub 2005 Oct 31. (Pubitemid 46211508)
51. Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol. 2002;20(2): 420-425. (Pubitemid 34072524)
52. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22(11):2101-2107. (Pubitemid 41095143)
53. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128(4):214-218. Epub 2002 Mar 12. (Pubitemid 34280379)
54. Hofmann M, Kiecker F, Wurm R, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol. 2006;76(1):59-64. (Pubitemid 43115761)
55. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005;103(12):2590-2597. (Pubitemid 40800539)
56. Krown SE, Niedzwiecki D, Hwu WJ, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006;107(8): 1883-1890. (Pubitemid 44582959)
57. Majer M, Jensen RL, Shrieve DC, et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer. 2007;110(6):1329-1337. (Pubitemid 47435606)
58. Eton O, Talpaz M, Lee KH, et al. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma. Cancer. 1996;77(5):893-899. (Pubitemid 26061282)
59. Savas B, Arslan G, Gelen T, et al. Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res. 1999;19(5C):4413-4420. (Pubitemid 30042799)
60. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357. (Pubitemid 46218728)
61. Hurst R, White DE, Heiss J, et al. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? J Immunother. 1999;22(4):356-362. (Pubitemid 29309968)
62. Voelter V, Pica A, Laurent J, et al. An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immun. 2008;8:6.
63. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105(23):8061-8066. Epub 2008 Jun 3. (Pubitemid 351904708)
64. Groves MD. Leptomeningeal metastasis: still a challenge. ASCO Educational Book. 2008:80-87.
65. Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitisrelated encephalopathy. J Neurooncol. 2005;72(2):185-189.
66. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106(9):2021-2027. (Pubitemid 43673219)
67. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94(10): 2675-2680. (Pubitemid 34478083)
68. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402.